Delivery Order SPE2DB24D2105-SPE2DB25FAQBR
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $1,853.05 on August 7, 2025, for the supply of Novolog 100 Unit/mL Flexpen 3mL insulin pens. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the prime contractor. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 8, 2025. As a child order under a...
- The Defense Logistics Agency awarded a $5,863.86 delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of August 21, 2025. The product will be delivered to the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a $12,030.04 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of NovoLog 100 Unit/ML FlexPen 3ML insulin pens. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 4, 2025. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of Novolog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $1,206.33 and a firm fixed-price structure. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The contract is set to be...
- The Defense Logistics Agency awarded a delivery order valued at $1,405.80 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded transaction. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of August 26, 2025. This order falls under...
- The Defense Logistics Agency awarded a $2,661.40 delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This contract represents a competitive, non-set-aside award under a firm fixed-price arrangement with an ultimate completion date of August 18, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters....
- The Defense Logistics Agency awarded a delivery order valued at $3,173.46 to AmerisourceBergen Drug Corp for Novolog 100 Unit/ML FlexPen 3ML insulin pens on August 4, 2025, with completion scheduled for August 5, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Novolog 100 Unit/ML FlexPen 3ML insulin pens, valued at $7,663.20. This is a firm fixed-price delivery order issued on June 18, 2025, with completion scheduled for June 20, 2025. The contract was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,380.61 for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of June 2, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $7,027.17 to AmerisourceBergen Drug Corp for the supply of Novolog 100 Unit/mL FlexPen 3mL insulin pens. The contract, issued on April 30, 2025, with an ultimate completion date of May 1, 2025, represents a firm fixed price delivery order with no set-aside designation, indicating competitive award. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a...
- SPE2DB24D2105Indefinite Delivery Contract
- SPE2DB24D2105-SPE2DB25FAQBRDelivery Order
The Defense Logistics Agency awarded a $27,329.09 delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Novolog 100 Unit/ml FlexPen 3ml insulin pens. The contract, which is not set aside for any particular business category, utilizes firm fixed pricing and requires completion by August 18, 2025. AmerisourceBergen will perform the work from its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion vehicle running through December 2026 that enables the company to supply pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly serving military and veteran healthcare systems through the Defense Logistics Agency. The company has demonstrated substantial capability in fulfilling federal pharmaceutical needs through its extensive contract portfolio, which includes diabetes medications, neurological treatments, pain management pharmaceuticals, and specialized medical supplies. This specific delivery order for insulin pens exemplifies the company's role in supplying essential medications to support the Defense Health Agency and other government healthcare systems through competitive procurement processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $27.3k | 8/15/25 |